News | October 12, 2021
Everest Organics develops API for molnupiravir
The drug is being developed at lab scale for the first-line of treatment of Covid-19
The drug is being developed at lab scale for the first-line of treatment of Covid-19
Harvard Medical School will deliver the first customized program, ‘Accelerate’, to create the next generation of leading experts in clinical development and medical affairs
Through this initiative, the Centre for Trauma will create curriculums and facilitate trauma-related courses for healthcare professionals at both urban and grassroot levels
AZD7442 reduced risk of developing severe Covid-19 or death in Tackle Phase III outpatient treatment trial
If authorized, molnupiravir could be the first oral antiviral medicine for the treatment of Covid-19
The company has enabled a transformation across three core areas with an investment target of US $ 150 million
The company will shift 100 percent of its energy use to renewable sources for both power and heat by 2025 in order to achieve carbon neutrality
Gantenerumab is an investigational antibody in Phase III development for early Alzheimer's disease (AD) and a comprehensive data set with an expected readout in mid-2022
The injection is used to reverse the effects of the muscle relaxants given to patients during surgery
The rolling submission to the U.S. FDA will begin in the fourth quarter of this year
Subscribe To Our Newsletter & Stay Updated
